Close Menu

NEW YORK – The US Food and Drug Administration alerted oncologists, researchers, and patients Tuesday afternoon that Genentech's atezolizumab (Tecentriq) plus paclitaxel did not benefit triple-negative breast cancer patients enrolled in the Phase III IMpassion131 trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.